Article thumbnail

Operational research in malawi: making a difference with cotrimoxazole preventive therapy in patients with tuberculosis and HIV

By Anthony D Harries, Rony Zachariah, Rhehab Chimzizi, Felix Salaniponi, Francis Gausi, Henry Kanyerere, Erik J Schouten, Andreas Jahn, Simon D Makombe, Frank M Chimbwandira and James Mpunga
Topics: Correspondence
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:3161891
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2010). AD: The published research paper: is it an important indicator of successful operational research at programme level? Trop Med Int Health
  2. AD: Voluntary counselling, HIV testing and adjunctive treatment with cotrimoxazole reduces mortality in tuberculosis patients in Thyolo,
  3. (2010). AG: Daily co-trimoxazole prophylaxis in severely immunosuppressed HIVinfected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort. Lancet
  4. (2005). Cotrimoxazole prophylaxis by HIV-infected persons in Uganda reduces morbidity and mortality among HIV-uninfected family members. AIDS
  5. (2005). CV: Impact of trimethoprim-sulfamethoxazole prophylaxis on falciparum malaria infection and disease.
  6. (2002). E: Cotrimoxazole prophylaxis in HIV-infected individuals after completing anti-tuberculosis treatment in Thyolo,
  7. (2008). Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa.
  8. (2004). Effect of cotrimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet
  9. (2004). Fine PEM: Cotrimoxazole prophylaxis reduces mortality in human immunodeficiency virus-positive tuberculosis patients in Karonga District, Malawi. Bull World Health Organ
  10. (2006). Freedberg KA: Cost-effectiveness Harries et al.
  11. (2005). Gilks CF: Effectiveness of cotrimoxazole prophylaxis on mortality in adults with tuberculosis in rural South Africa. AIDS
  12. (1999). Greenberg AE: Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Cote d’Ivoire: a randomised controlled trial. Lancet
  13. (2005). Health, Malawi: Co-trimoxazole preventive therapy for HIVpositive persons in Malawi.
  14. (2010). Health, Malawi: Malawi Antiretroviral Treatment Programme Quarterly Report. Results up to 31 st
  15. (2008). Health, Malawi: Treatment of AIDS. Guidelines for the use of Antiretroviral therapy in Malawi., Third
  16. (2007). Libamba E: Lower early mortality rate among patients receiving antiretroviral treatment at clinics offering cotrimoxazole prophylaxis in Malawi. J Acquir Immune Defic Syndr
  17. (2006). Libamba E: Scaling up antiretroviral therapy in resource-poor settings. Lancet
  18. (2004). Mpazanje R: Expanding antiretroviral therapy in Malawi: drawing on the country’s experience with tuberculosis. BMJ
  19. (2004). on behalf of the CHAP trial team: Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial. Lancet
  20. (2009). Operational research in low-income countries: what, why and how? Lancet Infect Dis
  21. (2006). Organization: Guidelines on co-trimoxazole prophylaxis for HIV-related infections among children, adolescents and adults. Recommendations for a public health approach.
  22. (2004). Organization/UNAIDS/UNICEF: Joint WHO/UNAIDS/UNICEF statement on use of cotrimoxazole as prophylaxis
  23. Putting Research into Policy and Practice.
  24. (2010). RF: Defining research to improve health systems. PLoS Medicine
  25. (2001). Salaniponi FM: Compliance with cotrimoxazole prophylaxis for the prevention of opportunistic infections in HIV-positive tuberculosis patients in Thyolo district,
  26. (2004). Salaniponi FM: Counselling, HIV testing and adjunctive cotrimoxazole for TB patients in Malawi: from research to routine implementation. Int J Tuberc Lung Dis
  27. (2002). Salaniponi FML: Changes in Escherichia coli resistance to cotrimoxazole in tuberculosis patients and in relation to co-trimoxazole prophylaxis in Thyolo, Malawi. Trans Roy Soc Trop Med Hyg
  28. (1999). Salaniponi FML: Treatment outcome of patients with smear-negative and smear-positive pulmonary tuberculosis in the National Tuberculosis Control Programme, Malawi. Trans Roy Soc Trop Med Hyg
  29. (2001). Salaniponi FML: Tuberculosis research in Malawi: making it count. Recent Advances and Research Updates
  30. (1999). the Cotrimo-CI study group: Early chemoprophylaxis with trimethorpim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Cote d’Ivoire: a randomised trial. Lancet
  31. (2011). Translating evidence into policy in low-income countries: lessons from co-trimoxazole preventive therapy. Bull World Health Organ
  32. (1998). Treatment outcome of an unselected cohort of tuberculosis patients in relation to human immunodeficiency virus serostatus in Zomba hospital, Malawi. Trans Roy Soc Trop Med & Hyg
  33. (2000). WHO: Provisional WHO/UNAIDS secretariat recommendations on the use of cotrimoxazole prophylaxis in adults and children living with HIV/AIDS
  34. (2005). Zijlstra EE: Efficacy and safety of two dosages of cotrimoxazole as preventive treatment for HIVinfected Malawian adults with new smear-positive tuberculosis. Trop Med Int Health